Last week Ventas, Inc. (VTR) was downgraded from “neutral” to “sell” by Goldman Sachs; however, other analysts have also recently downgraded the $12.6 billion healthcare REIT.
Mizuho cut Ventas from a “buy” rating to a “neutral” rating and set a $63.00 price target on the stock in a report on Monday, November 21st. Evercore ISI cut Ventas from a “hold” rating to an “underperform” rating in a report on Friday, March 3rd. Zacks Investment Research cut Ventas from a “hold” rating to a “sell” rating in a report on Monday, January 9th.
Three analysts have rated the stock with a sell rating and ten have given a hold rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $62.89
I have not reviewed any of the research reports from the other sell-side analysts, but I thought it would be a good time to take a deeper dive into Ventas to determine whether or not there is any reason to modify my current BUY recommendation.
Also, I’m gearing up for bracketology this week and I’ll be providing head-to-head analysis for Ventas and all other healthcare REITs. Consider this article somewhat of a scouting report, as I examine the pros and cons of Ventas as I determine whether or not the company will make it to the Final Four again this year.